The boy, whose cancer had returned rapidly after chemotherapy and surgery, was enrolled in the CARE study, the first human trial of a GPC3-CAR treatment. The therapy uses the patient's own T cells engineered to recognise glypican-3 (GPC3), a protein highly expressed in liver cancers, and also includes genes for interleukin-15 and interleukin-21 to boost the cells' longevity and killing ability.
Chimeric Antigen Receptor (CAR) T cell therapy has shown promise mainly against blood cancers, not solid tumours. This case suggests it may be effective against solid tumours as well.
When first diagnosed, the boy had a liver mass measuring 11.2 cm by 9.6 cm by 7.1 cm. Despite three rounds of chemotherapy, surgical removal of the primary tumour and two lung operations, the cancer recurred with a new lung tumour.
After the first infusion of the experimental treatment, the boy showed a partial response, with CT scans and falling alpha-fetoprotein levels indicating reduced tumour activity. He received a second dose eight weeks later, and follow-up scans showed no remaining signs of the disease, apart from some residual scarring. After 12 months, he remained disease-free.
"This case demonstrates that a durable complete response in a chemotherapy-resistant solid tumor can be achieved entirely in the outpatient setting without systemic toxicity," said first author and pediatric oncologist David Steffin from Baylor College of Medicine, Houston, Texas.
Co-author Andras Heczey, a pediatric oncologist at Seattle Children's Hospital and the University of Washington, said: "This study provides evidence that these novel CAR T cells may be a safe and effective modality for hepatoblastoma and highlights the need for further assessment in patients with GPC3+ solid tumors."
This is a single report of one patient in an early-phase trial. Continued testing is under way in the CARE study at Baylor College of Medicine and in a similar trial called IMPACT at Seattle Children's Hospital.
